1. At a Glance – The Silent Pharma Machine
₹1,228 crore market cap. ₹613 stock price. 22.5% return in 3 months. P/E of just 14. ROCE 17.3%. Debt almost zero.
And yet… nobody is screaming about it.
Lincoln Pharmaceuticals Ltd just delivered Q3 FY26 revenue of ₹166.32 crore and PAT of ₹28.60 crore, with quarterly profit up 37.7% YoY and sales up 13.5% YoY.
Exports contribute 62.6% of revenue. Domestic? 37.4%. This isn’t your local chemist shop story. This is a Gujarat-based pharma exporter quietly shipping formulations to 60+ countries while the market debates the next hot IPO.
Stock P/E: 14
Industry P/E: 28.3
Debt to equity: 0.00
Interest coverage: 105
Current ratio: 4.71
This is what financial discipline looks like when it doesn’t do Instagram reels.
But here’s the real question:
Is this a steady compounding pharma story… or just another mid-sized exporter riding currency winds?
Let’s open the strip pack and inspect.
2. Introduction – The Pharma Company That Doesn’t Shout
Founded in 1979. Survived the License Raj. Survived price controls. Survived global competition.
That alone deserves a medal.
Lincoln isn’t a flashy innovator like some biotech startups promising miracle molecules. It’s a formulation manufacturer. Meaning — it manufactures and sells finished pharmaceutical products across multiple therapeutic categories.
No dramatic R&D hype.
No billion-dollar molecule patents.
Just execution.
Over the years:
- 600+ formulations developed
- 1700 registered products
- 700 more in pipeline
- 7 patented products
- 25+ patent applications filed
And yet the market treats it like the middle child at a wedding — present, decent, unnoticed.
Exports at 62.6% means global exposure.
Domestic at 37.4% means India play intact.
But here’s what makes it interesting: It recently expanded its Cephalosporin plant at Mehsana, got WHO-GMP approvals, and entered Canada.
Small pharma companies don’t casually walk into regulated markets. That requires compliance muscles.
So now the real question:
Is Lincoln becoming a mini global formulation player… or will margins get squeezed like toothpaste?
3. Business Model – WTF Do They Even Do?
Let’s simplify.
Imagine pharma as three layers:
- Research new molecule (high risk, high reward)
- Manufacture bulk drug (API)
- Manufacture finished formulations (tablets, capsules, injections)
Lincoln plays in finished formulations.
It manufactures:
- Tablets
- Capsules
- Dry powder injections
- Oral liquids
- Ointments
- Ampoules
- Vials
Therapeutic spread? Huge.
From cough & cold to anti-diabetic to cardiac to anti-malarial to dermatology to CNS drugs.
Revenue mix Q3 FY25:
- Anti-infectives: 30.3%
- Musculoskeletal: 11.9%
- Respiratory: 8%
- Parasitology: 7.2%
- Cardiovascular: 5.7%
- Others: 29.2%
Translation: Diversified.
Now production capacity:
Khatraj and Mehsana
